Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock GlobeNewswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on CAPR
    Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
    4:05p ET November 4 '25 GlobeNewswire
    Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing InvestigationGlobeNewswireNovember 04, 2025

    SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

    Investors who have continuously held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact the firm to learn more:https://www.johnsonfistel.com/investigations/capricor-therapeutics-inc/

    You may be able to pursue changes to the company's corporate governance practices, seek the recovery of funds for the company, and request a court-approved incentive award, all at no cost to you. Please contact Johnson Fistel at (619) 814-4471 to learn more.

    About Johnson Fistel, PLLP:Johnson Fistel is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in derivative and securities class actions and has recovered over $90 million for clients while earning repeated recognition among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services.

    Attorney advertising.Past results do not guarantee future outcomes.Services may be performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication.

    Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations, (619) 814-4471jimb@johnsonfistel.com

    COMTEX_470029935/2010/2025-11-04T16:05:14

    SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

    Investors who have continuously held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact the firm to learn more:https://www.johnsonfistel.com/investigations/capricor-therapeutics-inc/

    You may be able to pursue changes to the company's corporate governance practices, seek the recovery of funds for the company, and request a court-approved incentive award, all at no cost to you. Please contact Johnson Fistel at (619) 814-4471 to learn more.

    About Johnson Fistel, PLLP:Johnson Fistel is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in derivative and securities class actions and has recovered over $90 million for clients while earning repeated recognition among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services.

    Attorney advertising.Past results do not guarantee future outcomes.Services may be performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication.

    Contact:Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations, (619) 814-4471jimb@johnsonfistel.com

    COMTEX_470029935/2010/2025-11-04T16:05:14

    Capricor Therapeutics Announces Proposed Public Offering of Common St...
    4:00p ET December 4 '25 GlobeNewswire
    Capricor Therapeutics Announces Positive Topline Results from Pivotal...
    7:19a ET December 3 '25 GlobeNewswire
    Capricor Therapeutics Presents New Data Demonstrating a Scalable Fram...
    9:00a ET November 24 '25 GlobeNewswire
    Capricor Therapeutics Reports Third Quarter 2025 Financial Results an...
    4:01p ET November 10 '25 GlobeNewswire
    Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Cont...
    10:16a ET November 10 '25 GlobeNewswire
    Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz ...
    11:21a ET November 9 '25 ACCESSWIRE
    Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johns...
    4:05p ET November 4 '25 GlobeNewswire
    Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, ...
    11:10a ET November 4 '25 ACCESSWIRE
    Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines D...
    9:15a ET November 3 '25 GlobeNewswire
    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against...
    11:14a ET November 2 '25 ACCESSWIRE

    Market data provided by News provided by